Search

Your search keyword '"Belhadj, Karim"' showing total 516 results

Search Constraints

Start Over You searched for: Author "Belhadj, Karim" Remove constraint Author: "Belhadj, Karim"
516 results on '"Belhadj, Karim"'

Search Results

1. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

2. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

3. Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions

4. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

5. Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France

6. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study

7. Serological responses against seasonal influenza viruses in patients with multiple myeloma treated or untreated with daratumumab after two doses of tetravalent vaccine

9. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

10. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

12. Existence results to Steklov system involving the (p, q)-Laplacian

13. Existence and non-existence of solutions for a (p,q)-Laplacian Steklov system

14. Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network

15. Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study

16. Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

17. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

18. Heart Transplantation, Either Alone or Combined With Liver and Kidney, a Viable Treatment Option for Selected Patients With Severe Cardiac Amyloidosis

19. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

20. On a positive solutions for $(p,q)$-Laplacian Steklov problem with two parameters

21. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

22. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

23. P-287 Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma in real life context in France: IMAGE subgroup analysis based on subgroups of interest

24. RAS/RAF landscape in monoclonal plasma cell conditions

28. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

29. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

30. Data from The Genetic Basis of Hepatosplenic T-cell Lymphoma

31. Supplementary Tables S1 - S10 from The Genetic Basis of Hepatosplenic T-cell Lymphoma

32. Supplementary Methods, Figures S1 - S9 from The Genetic Basis of Hepatosplenic T-cell Lymphoma

33. Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma

34. Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study

35. Prognostic value of positron emission tomography/computed tomography in transplanteligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

36. On a positive solution for $(p,q)$-Laplace equation with Nonlinear

37. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

38. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

39. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study

40. Existence and non-existence of positive solution for (p, q)-Laplacian with singular weights

41. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

42. Existence and multiplicity results for a Steklov problem involving (p(x), q(x))-Laplacian operator

43. Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

44. Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

45. Outcome of Patients with Primary Mediastinal Large B-Cell Lymphoma after R-CHOP21, R-CHOP14 and R-ACVBP: A Pooled Analysis of Clinical Trials from Lysa

47. Existence and multiplicity of $a$-harmonic solutions for a Steklov problem with variable exponents

48. Existence and multiplicity results for elliptic problems with Nonlinear Boundary Conditions and variable exponents

49. Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

50. Heterogeneity in long term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients

Catalog

Books, media, physical & digital resources